Syndax Leverages Novel IP for Cash, Phase II HDAC
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.